Completed PHASE3 INTERVENTIONAL 2-arm NCT01120600

A Study to Assess Safety and Efficacy of Odanacatib (MK-0822) in Men With Osteoporosis (MK-0822-053)

A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) in the Treatment of Men With Osteoporosis Treated With Vitamin D and Calcium

Sponsor: Merck Sharp & Dohme LLC

Conditions Osteoporosis

Interventions Calcium carbonate Odanacatib Placebo for Odanacatib Vitamin D3

Updated 9 times since 2017 Last updated: Jul 30, 2018 Started: Jun 9, 2010 Primary completion: Jul 22, 2013 Completion: Jul 22, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Osteoporosis, this trial is completed. The trial is conducted by Merck Sharp & Dohme LLC and has accumulated 9 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jun 2022 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Jun 2022 [monthly]

Completed PHASE3
Sep 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 4 earlier versions

Jun 2018 — Sep 2018 [monthly]

Completed PHASE3
Dec 2017 — Jun 2018 [monthly]

Completed PHASE3
Feb 2017 — Dec 2017 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jun 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck Sharp & Dohme LLC

Data source: Merck Sharp & Dohme LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.